Special Issue on Lymphoma

Submission Deadline: Mar. 10, 2020

Please click the link to know more about Manuscript Preparation: http://www.ijcocr.org/submission

Please download to know all details of the Special Issue

Special Issue Flyer (PDF)
  • Lead Guest Editor
    • Anil Tombak
      Department of Internal Medicine, Mersin University, Mersin, Turkey
  • Guest Editor
    Guest Editors play a significant role in a special issue. They maintain the quality of published research and enhance the special issue’s impact. If you would like to be a Guest Editor or recommend a colleague as a Guest Editor of this special issue, please Click here to complete the Guest Editor application.
    • Elif Birtas Atesoglu
      Anadolu Saglik Merkezi,  Kocaeli, Turkey
    • Mahmut Yeral
      Baskent University, Ankara, Turkey
    • Ozgur Mehtap
      Kocaeli University, Kocaeli, Turkey
    • Demircan Ozbalci
      Suleyman Demirel University, Almaty, Turkey
    • Gökhan Özgür
      Department of Hematology, Ankara, Turkey
    • Fusun Gediz
      Bozyaka Research and Training Hospital, Izmir, Turkey
    • Indranil Chakrabarti
      Department of Pathology, North Bengal Medical College, Siliguri, West Bengal, India
  • Introduction

    Lymphomas consists of a diverse group of malignant neoplasms. They derived from B cell progenitors, T cell progenitors, mature B cells, mature T cells, or natural killer cells. The World Health Organization (WHO) classifies tumors of the hematopoietic and lymphoid tissues according to their morphologic, immunophenotypic, genetic, and clinical features and this classification was revised in 2016. The pathogenesis of lymphomas still continues to dissolve and new biological subtypes are identified, and new information is added. These developments and changes bring new suggestions for the diagnostic, prognostic evaluation and treatment of lymphomas. A large number of new agents were introduced for the the treatment of lymphomas in the last 20 years. New monoclonal antibodies and targeted agents acting on each of its specific mechanisms have been successfully applied to different lymphoma subtypes. In addition, phase studies of many agents are still ongoing, and the introduction of a significant number of patients into these studies is a necessity in today's lymphoma treatment practice.

    Aims and Scope:

    1. Lymphoma
    2. Chemotherapy
    3. Antibodies
    4. Biology
    5. Small molecules
    6. Molecular pathogenesis

  • Guidelines for Submission

    Manuscripts can be submitted until the expiry of the deadline. Submissions must be previously unpublished and may not be under consideration elsewhere.

    Papers should be formatted according to the guidelines for authors (see: http://www.ijcocr.org/submission). By submitting your manuscripts to the special issue, you are acknowledging that you accept the rules established for publication of manuscripts, including agreement to pay the Article Processing Charges for the manuscripts. Manuscripts should be submitted electronically through the online manuscript submission system at http://www.sciencepublishinggroup.com/login. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal and will be listed together on the special issue website.